MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Elenco Azioni・Sangamo Therapeutics Inc

Sangamo Therapeutics Inc

Chiusa

SettoreSettore sanitario

0.26 -3.7

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

0.26

Massimo

0.27

Metriche Chiave
By Trading Economics
Entrata	-2.5M -37M
Vendite	14M 14M
EPS	-0.111
Margine di Profitto	-262.996
Dipendenti	142
EBITDA	10M -23M

Raccomandazioni
By TipRanks
Raccomandazioni	Acquista
Previsioni per 12 mesi	+2122.22% upside

Dividendi
By Dow Jones
Utili prossimi	11 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-18M 106M
Apertura precedente	3.96
Chiusura precedente	0.26

Notizie sul Sentiment di mercato

By Acuity

39%

61%

140 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

0.5207 / 0.7223 Supporto e resistenza

Sangamo Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 apr 2026, 20:26 UTC

Acquisizioni, Fusioni, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17 apr 2026, 18:15 UTC

Principali Notizie su Eventi

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17 apr 2026, 16:49 UTC

Principali Notizie su Eventi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17 apr 2026, 16:49 UTC

Principali Notizie su Eventi

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17 apr 2026, 22:58 UTC

Utili

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17 apr 2026, 21:32 UTC

Discorsi di Mercato

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17 apr 2026, 21:22 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 apr 2026, 21:22 UTC

Discorsi di Mercato

Moody's Downgrades Belgium to A1 -- Market Talk

17 apr 2026, 20:52 UTC

Utili

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17 apr 2026, 20:50 UTC

Discorsi di Mercato

Utili

Acquisizioni, Fusioni, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 apr 2026, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

17 apr 2026, 20:29 UTC

Utili

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17 apr 2026, 20:11 UTC

Acquisizioni, Fusioni, Takeovers

UCB to Buy Neurona Therapeutics for Up to $1.15B

17 apr 2026, 19:34 UTC

Discorsi di Mercato

Utili

Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

17 apr 2026, 19:34 UTC

Discorsi di Mercato

Utili

Acquisizioni, Fusioni, Takeovers

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17 apr 2026, 19:31 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17 apr 2026, 19:26 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Edge Up -- Market Talk

17 apr 2026, 19:21 UTC

Discorsi di Mercato

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17 apr 2026, 19:15 UTC

Discorsi di Mercato

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17 apr 2026, 19:07 UTC

Discorsi di Mercato

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17 apr 2026, 18:57 UTC

Principali Notizie su Eventi

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17 apr 2026, 18:53 UTC

Acquisizioni, Fusioni, Takeovers

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17 apr 2026, 18:53 UTC

Acquisizioni, Fusioni, Takeovers

UCB 2026 Rev Guidance Unchanged

17 apr 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17 apr 2026, 18:52 UTC

Acquisizioni, Fusioni, Takeovers

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17 apr 2026, 18:14 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17 apr 2026, 18:00 UTC

Principali Notizie su Eventi

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17 apr 2026, 18:00 UTC

Principali Notizie su Eventi

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17 apr 2026, 17:31 UTC

Discorsi di Mercato

Principali Notizie su Eventi

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17 apr 2026, 17:26 UTC

Discorsi di Mercato

Utili

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Confronto tra pari

Modifica del prezzo

Sangamo Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

2122.22% in crescita

Previsioni per 12 mesi

Media 6 USD 2122.22%

Alto 10 USD

Basso 2 USD

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sangamo Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 2 che hanno fornito valutazioni azionarie a Sangamo Therapeutics Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

0.5207 / 0.7223Supporto e resistenza

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Sentiment

By Acuity

140 / 348 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.